# US 12,178,796 B2 · Drug-loaded nanofiber membrane, method for preparing the same, and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,178,796 B2
- Document ID: US12178796B2
- Status: Granted
- Kind: B2
- Application number: 17/467,427
- Filed: 2021-09-06
- Published: 2021-12-23
- Granted: 2024-12-31
- Earliest claimed: 2019-03-15
- Assignees: Shenzhen Guangyuan Biomaterial Co., Ltd.
- Applicants: Shenzhen Guangyuan Biomaterial Co., Ltd.
- Inventors: Zhichao Han; Shanshan Xu; Jia'en Wu
- Web page: https://patentgrep.com/patent/US12178796B2

## CPC

- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/545: Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: [IMAGE cpc-sch-A61K-0953.gif] , e.g. cephalosporins, {cefaclor, or cephalexine}
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- D01D 5/0038: {the fibre formed by solvent evaporation, i.e. dry electro-spinning}
- D01D 5/0069: {characterised by the spinning section, e.g. capillary tube, protrusion or pin}
- D01F 1/10: Other agents for modifying properties
- D01F 6/625: {derived from hydroxy-carboxylic acids, e.g. lactones}
- D01F 6/84: from copolyesters
- D04H 1/435: Polyesters
- D04H 1/4382: Stretched reticular film fibres; Composite fibres; Mixed fibres; Ultrafine fibres; Fibres for artificial leather
- D04H 1/728: by electro-spinning {(electro-spinning methods and apparatus D01D5/0007)}
- D10B 2509/022: Wound dressings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- D01D: MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01F: CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D04H: MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL (weaving D03; knitting D04B; braiding D04C; net-making D04G; sewing D05B; tufting D05C; finishing non-woven fabrics D06); FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING {; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION}(non-woven fabrics having an intermediate or external layer of a different kind, e.g. of woven fabric, B32B)
- D10B: INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES

## Abstract

A drug-loaded nanofiber membrane includes a first fiber, a second fiber, and a drug. The drug is dispersed into the first fiber. The first fiber includes poly(lactic-co-glycolic acid) copolymer (PLGA copolymer), and the second fiber includes poly(p-dioxanone) (PDO).

## Claims

### Claim 1

A drug-loaded nanofiber membrane comprising a first fiber and a second fiber; the first fiber comprises poly(lactic-co-glycolic acid) copolymer (PLGA copolymer) and a drug dispersed within the first fiber, and the second fiber comprises poly(p-dioxanone) (PDO);
wherein:
the PLGA copolymer is a mixture consisting of a high-molecular weight PLGA copolymer and a low-molecular weight PLGA copolymer; the high-molecular weight refers to a viscosity-average molecular weight of 100,000 to 150,000 Da, and the low-molecular weight refers to a viscosity-average molecular weight of 40,000 to 80,000 Da;
a mass ratio of the high-molecular weight PLGA copolymer to the low-molecular weight PLGA copolymer is between 25:75 and 3:97; and
a total mass of the second fiber accounts for 1%-25% of a total mass of the first fiber.

### Claim 2 (depends on 1)

The membrane of claim 1, wherein the total mass of the second fiber accounts for 1%-15% of a total mass of the first fiber.

### Claim 3 (depends on 1)

The membrane of claim 1, wherein a molar ratio of lactic acid unit to hydroxyacetic acid unit in the PLGA copolymer is between 1:1 and 9:1.

### Claim 4 (depends on 1)

The membrane of claim 1, wherein a molecular weight of PDO is 60000-250,000 Da.

### Claim 5 (depends on 1)

The membrane of claim 1, wherein the drug comprises an antibiotic drug, an anti-tumor drug, an anti-inflammatory drug, or a combination thereof.

### Claim 6 (depends on 5)

The membrane of claim 5, wherein the drug comprises ciprofloxacin, ciprofloxacin hydrochloride, moxifloxacin, levofloxacin, cefradine, tinidazole, 5-fluorouracil, adriamycin, cisplatin, paclitaxel, gemcitabine, capecitabine, aspirin, indomethacin, or a combination thereof.

### Claim 7 (depends on 1)

The membrane of claim 1, wherein a total mass of the drug accounts for 1%-35% of a total mass of the first fiber and the second fiber.

### Claim 8

A drug-loaded nanofiber membrane comprising a first fiber, a second fiber, and a drug dispersed into the first fiber; the first fiber comprising poly(lactic-co-glycolic acid) copolymer (PLGA copolymer), and the second fiber comprising poly(p-dioxanone) (PDO);
wherein:
the PLGA copolymer is a mixture of a high-molecular weight PLGA copolymer and a low-molecular weight PLGA copolymer; the high-molecular weight refers to a viscosity-average molecular weight of 100,000 to 150,000 Da, and the low-molecular weight refers to a viscosity-average molecular weight of 60,000 to 80,000 Da;
a mass ratio of the high-molecular weight PLGA copolymer to the low-molecular weight PLGA copolymer is between 25:75 and 3:97; and
a total mass of the second fiber accounts for 1%-25% of a total mass of the first fiber.

### Claim 9 (depends on 8)

The membrane of claim 8, wherein the low-molecular weight refers to a viscosity-average molecular weight of 70,000 to 80,000 Da.